NA Bladder Disorders Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143126
- Pages: 225
-
Format:
Short Description
North America Bladder Disorders Market- By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical and others), End User (Hospitals, Clinics, Ambulatory Surgery Centres, Others), Distribution Channel (Direct, Retail) Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029
Market Definition:
Bladder-related disorders include Cystitis - inflammation of the bladder, often from infection, Urinary incontinence - loss of bladder control, Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.
The doctors perform different tests to diagnose the bladder disorder, including x-rays, urine tests, and a bladder wall examination by scope called a cystoscope. The treatment of the disorder depends on the cause of the problem, including medication, surgeries (in severe cases), and non-surgical procedures.
Anticholinergic medications are the first line of pharmacotherapy for Over-active Bladder (OAB) syndrome. OAB is a clinical symptom characterized by the urgency of the desire to pass urine, which is difficult to defer. Generally, the frequency of passing urine more than eight times per day is considered in OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle, reducing bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. The majority of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.
Market Segmentation:
The North America bladder disorders market is categorized into four segments: type, treatment type, end user, and distribution channel.
On the basis of type, the North America bladder disorders market is segmented into Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer
On the basis of treatment type, the North America bladder disorders market is segmented into Surgery, Medication, Non-surgical, and others.
On the basis of end-user, the North America bladder disorders market is segmented into Hospitals, Clinics, Ambulatory Surgery Centres, Others
On the basis of distribution channel, the North America bladder disorders market is segmented into direct and retail
Market Players
The major companies which are dealing in the North America bladder disorders market are listed below:
Medtronic
Laborie
Boston Scientific Corporation
Pfizer Inc.
Astellas Pharma Inc.
KYORIN Pharmaceutical Co., Ltd. (A subsidiary of KYORIN Holdings, Inc.)
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc.
Axonics, Inc.
Merck & Co., Inc.
Viatris Inc.
Blue Wind Medical
Valencia Technologies
Gaylord Chemical Company, L.L.C.
Coloplast Corp, AbbVie Inc.
Sun Pharmaceutical Industries Ltd.
Zydus Group
Urovant Sciences, among others.
TABLE OF CONTENTS
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF NORTH AMERICA BLADDER DISORDERS MARKET 23
1.4 LIMITATIONS 24
1.5 MARKETS COVERED 25
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 TYPE LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 MARKET END USER COVERAGE GRID 36
2.11 VENDOR SHARE ANALYSIS 37
2.12 SECONDARY SOURCES 38
2.13 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 41
4.1 PESTEL ANALYSIS 42
4.2 PORTER'S FIVE FORCES 43
4.3 NORTH AMERICA BLADDER DISORDERS MARKET, PIPELINE ANALYSIS 44
5 NORTH AMERICA BLADDER DISORDER MARKET: REGULATIONS 45
5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION 45
5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS 45
5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS 46
6 NORTH AMERICA BLADDER DISORDERS MARKET OVERVIEW 48
6.1 DRIVERS 50
6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 50
6.1.2 GROWING GERIATRIC POPULATION 50
6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS 51
6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES 51
6.2 RESTRAINTS 52
6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT 52
6.2.2 PRODUCTS RECALLS FROM MARKET 52
6.3 OPPORTUNITIES 52
6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS 52
6.3.2 RISING DISEASE MANAGEMENT PROGRAMS 53
6.4 CHALLENGES 54
6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS 54
6.4.2 PATENT EXPIRY OF DRUGS 54
7 NORTH AMERICA BLADDER DISORDERS MARKET, BY TYPE 56
7.1 OVERVIEW 57
7.2 OVERACTIVE BLADDER 60
7.3 URINARY INCONTINENCE 60
7.4 CYSTITIS 61
7.5 INTERSTITIAL CYSTITIS 62
7.6 BLADDER CANCER 63
7.7 OTHERS 64
8 NORTH AMERICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE 65
8.1 OVERVIEW 66
8.2 MEDICATION 69
8.2.1 TOLTERODINE 70
8.2.2 MIRABEGRON 70
8.2.3 FESOTERODINE 70
8.2.4 OXYBUTYNIN 70
8.2.5 SOLIFENACIN 70
8.2.6 DARIFENACIN 70
8.2.7 TROSPIUM 70
8.2.8 OTHERS 71
8.3 SURGERY 71
8.3.1 SURGERY TO INCREASE BLADDER CAPACITY 72
8.3.2 BLADDER REMOVAL 72
8.3.3 OTHERS 72
8.4 OTHERS 72
9 NORTH AMERICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL 74
9.1 OVERVIEW 75
9.2 DIRECT 78
9.3 RETAIL 78
10 NORTH AMERICA BLADDER DISORDERS MARKET, BY END USER 80
10.1 OVERVIEW 81
10.2 HOSPITALS 84
10.3 CLINICS 85
10.4 AMBULATORY SURGICAL CENTERS 85
10.5 OTHERS 86
11 NORTH AMERICA BLADDER DISORDERS MARKET, BY GEOGRAPHY 88
11.1 NORTH AMERICA 89
11.1.1 U.S. 96
11.1.2 CANADA 98
11.1.3 MEXICO 100
12 NORTH AMERICA BLADDER DISORDERS MARKET: COMPANY LANDSCAPE 102
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 102
13 SWOT ANALYSIS 103
14 COMPANY PROFILE 104
14.1 MERCK AND CO. INC. (2021) 104
14.1.1 COMPANY SNAPSHOT 104
14.1.2 REVENUE ANALYSIS 104
14.1.3 COMPANY SHARE ANALYSIS 105
14.1.4 PRODUCT PORTFOLIO 105
14.1.5 RECENT DEVELOPMENT 105
14.2 ASTELLAS PHARMA INC. (2021) 106
14.2.1 COMPANY SNAPSHOT 106
14.2.2 REVENUE ANALYSIS 106
14.2.3 COMPANY SHARE ANALYSIS 107
14.2.4 PRODUCT PORTFOLIO 107
14.2.5 RECENT DEVELOPMENTS 107
14.3 BRISTOL-MYERS SQUIBB COMPANY (2021) 109
14.3.1 COMPANY SNAPSHOT 109
14.3.2 REVENUE ANALYSIS 109
14.3.3 COMPANY SHARE ANALYSIS 110
14.3.4 PRODUCT PORTFOLIO 110
14.3.5 RECENT DEVELOPMENT 110
14.4 BOSTON SCIENTIFIC CORPORATION (2021) 111
14.4.1 COMPANY SNAPSHOT 111
14.4.2 REVENUE ANALYSIS 111
14.4.3 COMPANY SHARE ANALYSIS 112
14.4.4 PRODUCT PORTFOLIO 112
14.4.5 RECENT DEVELOPMENT 112
14.5 VIATRIS INC. (2021) 113
14.5.1 COMPANY SNAPSHOT 113
14.5.2 REVENUE ANALYSIS 113
14.5.3 COMPANY SHARE ANALYSIS 114
14.5.4 PRODUCT PORTFOLIO 114
14.5.5 RECENT DEVELOPMENT 114
14.6 ABBVIE (2021) 115
14.6.1 COMPANY SNAPSHOT 115
14.6.2 REVENUE ANALYSIS 115
14.6.3 PRODUCT PORTFOLIO 116
14.6.4 RECENT DEVELOPMENT 116
14.7 AXONICS, INC. (2021) 117
14.7.1 COMPANY SNAPSHOT 117
14.7.2 REVENUE ANALYSIS 117
14.7.3 PRODUCT PORTFOLIO 117
14.7.4 RECENT DEVELOPMENT 118
14.8 BLUE WIND MEDICAL (2021) 119
14.8.1 COMPANY SNAPSHOT 119
14.8.2 PRODUCT PORTFOLIO 119
14.8.3 RECENT DEVELOPMENT 119
14.9 COLOPLAST CORP. (2021) 120
14.9.1 COMPANY SNAPSHOT 120
14.9.2 REVENUE ANALYSIS 120
14.9.3 PRODUCT PORTFOLIO 121
14.10 GAYLORD CHEMICAL COMPANY, LLC (2021) 122
14.10.1 COMPANY SNAPSHOT 122
14.10.2 PRODUCT PORTFOLIO 122
14.10.3 RECENT DEVELOPMENT 122
14.11 JOHNSON & JOHNSON SERVICES, INC. (2021) 123
14.11.1 COMPANY SNAPSHOT 123
14.11.2 REVENUE ANALYSIS 123
14.11.3 PRODUCT PORTFOLIO 124
14.11.4 RECENT DEVELOPMENT 124
14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021) 125
14.12.1 COMPANY SNAPSHOT 125
14.12.2 PRODUCT PORTFOLIO 125
14.12.3 RECENT DEVELOPMENTS 126
14.13 LABORIE (2021) 127
14.13.1 COMPANY SNAPSHOT 127
14.13.2 PRODUCT PORTFOLIO 127
14.13.3 RECENT DEVELOPMENT 128
14.14 MEDTRONIC (2021) 129
14.14.1 COMPANY SNAPSHOT 129
14.14.2 REVENUE ANALYSIS 129
14.14.3 PRODUCT PORTFOLIO 130
14.14.4 RECENT DEVELOPMENTS 130
14.15 PFIZER INC. (2021) 131
14.15.1 COMPANY SNAPSHOT 131
14.15.2 REVENUE ANALYSIS 131
14.15.3 PRODUCT PORTFOLIO 132
14.15.4 RECENT DEVELOPMENTS 132
14.16 VALENCIA TECHNOLOGIES (2021) 133
14.16.1 COMPANY SNAPSHOT 133
14.16.2 PRODUCT PORTFOLIO 133
14.16.3 RECENT DEVELOPMENT 134
14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021) 135
14.17.1 COMPANY SNAPSHOT 135
14.17.2 REVENUE ANALYSIS 135
14.17.3 PRODUCT PORTFOLIO 136
14.17.4 RECENT DEVELOPMENT 136
14.18 SWATI SPENTOSE (2021) 137
14.18.1 COMPANY SNAPSHOT 137
14.18.2 PRODUCT PORTFOLIO 137
14.18.3 RECENT DEVELOPMENT 137
14.19 UROVANT SCIENCES (2021) 138
14.19.1 COMPANY SNAPSHOT 138
14.19.2 PRODUCT PORTFOLIO 138
14.19.3 RECENT DEVELOPMENT 138
14.20 ZYDUS GROUP (2021) 139
14.20.1 COMPANY SNAPSHOT 139
14.20.2 PRODUCT PORTFOLIO 139
14.20.3 RECENT DEVELOPMENT 139
15 QUESTIONNAIRE 140
16 RELATED REPORTS 143
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
